 |
| GETTY IMAGES |
David Solomon is sharpening the axe again.
The Goldman Sachs CEO will slash more than 1,300 jobs as part of the bank’s ongoing review to cull poor performers, the Wall Street Journal reported on Friday
Goldman’s cuts will affect between 3% and 4% of Goldman’s 45,000-strong workforce, the Journal added, citing people familiar with the matter.
The layoffs have already started and will continue through the fall, according to the Journal, under the bank’s annual review process known as “strategic resource assessment.”
“Our annual talent reviews are normal, standard, and customary, but otherwise unremarkable,” Tony Fratto, a Goldman spokesman, told the newspaper.
He added that headcount would be higher at the end of 2024, compared to the end of last year.
The bank regularly seeks to cut back on between 2% and 7% of its workforce each year based on various performance factors, market conditions and its financial outlook.
Last year, the exercise reportedly resulted in cuts between 1% and 5% of employees losing their jobs.
Goldman reinstated performance-related job culls in 2022 after it was halted for two years owing to the COVID-19 pandemic. --->READ MORE HERE
 |
| AFP |
A main ingredient in the popular weight loss drugs Wegovy and Ozempic has been linked to fewer COIVD-19 deaths, according to a report.
People being treated with a 2.4 mg dose of the drug semaglutide, the active ingredient in Wegovy and Ozempic, still became infected with COVID but were 33% less likely to die, CNBC reported, citing a number of studies released last Friday by the Journal of the American College of Cardiology.
The research indicates that semaglutide may have wide health benefits beyond reducing the risk of cardiovascular events like heart attacks and strokes, the report said.
Benjamin Scirica, a co-author of the study, said patients who received semaglutide in his study had a 29% reduction in deaths from causes not related to cardiovascular events, noting that weight did not appear to be a "major mediator" in the results.
Scirica, a professor of medicine at Harvard Medical School, said the findings were "surprising."
"The fact that semaglutide reduced non-cardiovascular death, and in particular COVID-19-related deaths, was surprising. It opens up new avenues for exploring how this class of drugs may benefit patients," Scirica said in an article published by the Harvard Gazette.
More than 17,000 people who were overweight or obese and who suffered from heart ailments, participated in the study, CNBC said. --->READ MORE HEREFollow links below to relevant/related stories and resources:
How COVID-19 and blood pressure should be closely monitored for your health
Novavax wins FDA emergency approval for updated Covid-19 vaccine
USA TODAY: Coronavirus Updates
WSJ: Coronavirus Live Updates
YAHOO NEWS: Coronavirus Live Updates
NEW YORK POST: Coronavirus The Latest
If you like what you see, please "Like" and/or Follow us on FACEBOOK here, GETTR here, and TWITTER here.
No comments:
Post a Comment